Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications.
- Could you give us a brief overview of the health burden of Crohn’s disease and colitis? (0:10)
- What therapies are available to help manage symptoms of Crohn’s and colitis? (1:44)
Disclosures: Gil Melmed discloses consulting for Abbvie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Genetech, Pfizer, Samsung Bioepis, Takeda, Shionogi, Prometheus Labs, Techlab, Fresenius Kabi, and Amgen; and receiving grant/ research support from Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
To find out more visit our gastroenterology content here.
Share this Video
Related Videos In Digestive Disorders
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Jean-Frederic Colombel, ECCO 2023: A sub-analysis investigating upadacitinib for rapid symptom relief in Crohn’s disease
The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss his sub-analysis of the data from U-EXCEL […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!